Optimization and In vivo Evaluation of Quetiapine Loaded Transdermal Drug Delivery System for the Treatment of Schizophrenia.

Optimization and In vivo Evaluation of Quetiapine Loaded Transdermal Drug Delivery System for the Treatment of Schizophrenia. Drug Dev Ind Pharm. 2020 Sep 08;:1-34 Authors: Agrawal MB, Patel MM Abstract The prevailing studies were carried out to formulate and optimize the quetiapine transdermal matrix patch by the usage of Box-Behnken design for ameliorated bioavailability when contrasted with conventional drug delivery. The Box-Behnken design with 3-level and 3-factor was utilized to explore the intermingle impact of critical attributes on tensile strength, in vitro drug release, and flux. Optimized formulation was characterized for Fourier transform infrared, differential scanning calorimetry, in-vivo pharmacokinetics, and skin irritation along with stability studies. The inference of the finalized batch (F14) depicted the flux of 51.81 ± 0.32 µg/h/cm2, TS of 6.46 ± 0.56 MPa and the % drug release after 20 h of 82.98 ± 1.48% with no remarkable variation even after six months stability studies. Correlation between predicted and the observed values of the dependent variables was very closer. Optimized quetiapine transdermal patch did not exert any symptoms of skin irritation. The bioavailability of quetiapine was enhanced almost 4.59 times after topical delivery when contrasted with the conventional dosage form. The outputs of the research work divulged that the developed matrix patch of quetiapine for transdermal...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research